{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-23-000101","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.495819+00:00","generated_at":"2026-06-08T04:40:08.222750+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Exagen Q3 rev $13.4M, net loss narrows to $5.4M; guides FY rev at least $50M","bullets":["Revenue $13.4M vs $14.7M YoY (included $3.7M one-time Medicare); net loss $(5.4)M vs $(8.1)M.","Adj. EBITDA improved to $(3.6)M from $(6.1)M YoY; gross margin 57.4% vs 59.2%.","Cash $28.4M at Sep 30, $31.4M at Oct 31; AVISE CTD ASP $320.","FY 2023 guidance: rev ≥$50M (record), adj. EBITDA ~$(20)M; expects improvement in 2024.","Exclusive license with Johns Hopkins to develop lupus nephritis biomarkers."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-23-000101","json":"https://secwatch.observer/filing/0001274737-23-000101.json","markdown":"https://secwatch.observer/filing/0001274737-23-000101.md","text":"https://secwatch.observer/filing/0001274737-23-000101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473723000101/0001274737-23-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473723000101/exdx-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:40:08.222750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c12a69f43c6845616b8dbe1bfccc7e3fd319e7cb","claim":"EXAGEN INC. reported the three and nine months ended September 30, 2023 results: revenue $13.4 million, net income $(5.4) million. Guidance reaffirmed.","evidence_excerpt":"Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. • Recognized total revenue of $13.4 million for the third quarter of 2023. • Delivered gross margin of 57.4% for the third quarter of 2023. • AVISE® CTD trailing twelve-month average selling price (ASP) of $320. • Net loss","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473723000101/0001274737-23-000101-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2023"},{"label":"Revenue","value":"$13.4 million"},{"label":"Net income","value":"$(5.4) million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}